The Association of HLA-Class I and Class II with Hodgkin’s Lymphoma in Iranian Patients
Table 2
The allele frequencies of HLA-A, HLA-B, HLA-DRB1 in HD patients and control groups.
Alleles
HD patients (%)
Controls (%)
valuea
PC valueb
OR (95% CI)c
HLA-A*01
15 (9%)
30 (10%)
0.67
>0.999
0.871 (0.361–2.098)
HLA-A*02
36 (21%)
63 (21%)
0.96
>0.999
1.011 (0.542–1.885)
HLA-A*03
20 (12%)
57 (19%)
0.04
0.546
0.568 (0.27–1.192)
HLA-A*11
17 (10%)
27 (9%)
0.72
>0.999
1.12 (0.472–2.654)
HLA-A*23
5 (3%)
9 (3%)
0.97
>0.999
0.98 (0.218–4.394)
HLA-A*24
36 (21%)
51 (17%)
0.26
>0.999
1.31 (0.688–2.491)
HLA-A*26
3 (2%)
15 (5%)
0.07
>0.999
0.341 (0.062–1.858)
HLA-A*29
5 (3%)
9 (3%)
0.97
>0.999
0.98 (0.218–4.394)
HLA-A*30
7 (4%)
12 (4%)
0.95
>0.999
1.03 (0.284–3.729)
HLA-A*31
5 (3%)
12 (4%)
0.55
>0.999
0.727 (0.173–3.050)
HLA-A*32
5 (3%)
6 (2%)
0.51
>0.999
1.48 (0.291–7.517)
HLA-A*33
6 (4%)
6 (2%)
0.31
>0.999
1.79 (0.379–8.447)
HLA-A*68
10 (6%)
3 (1%)
0.002
0.026
6.188 (1.059–36.053)
HLA-B*07
7 (4%)
15 (5%)
0.66
>0.999
0.816 (0.197–3.37)
HLA-B*08
2 (1%)
12 (4%)
0.08
>0.999
0.286 (0.027–2.947)
HLA-B*13
2 (1%)
9 (3%)
0.20
>0.999
0.38 (0.034–4.133)
HLA-B*14
2 (1%)
9 (3%)
0.20
>0.999
0.38 (0.034–4.133)
HLA-B*15
7 (4%)
9 (3%)
0.52
>0.999
1.38 (0.291–6.537)
HLA-B*18
5 (3%)
12 (4%)
0.55
>0.999
0.72 (0.139–3.71)
HLA-B*27
5 (3%)
8 (3%)
0.86
>0.999
1.1 (0.190–6.345)
HLA-B*35
34 (20%)
53 (18%)
0.53
>0.999
1.16 (0.553–2.431)
HLA-B*38
10 (6%)
16 (5%)
0.80
>0.999
1.1 (0.312–3.868)
HLA-B*39
7 (4%)
9 (3%)
0.52
>0.999
1.38 (0.291–6.537)
HLA-B*40
2 (1%)
6 (2%)
0.50
>0.999
0.583 (0.048–7.04)
HLA-B*41
2 (1%)
9 (3%)
0.20
>0.999
0.385 (0.035–4.188)
HLA-B*44
10 (6%)
28 (9%)
0.18
>0.999
0.607 (0.190–1.929)
HLA-B*48
2 (1%)
6 (2%)
0.50
>0.999
0.583 (0.048–7.04)
HLA-B*49
3 (2%)
12 (4%)
0.18
>0.999
0.431 (0.059–3.115)
HLA-B*50
3 (2%)
15 (5%)
0.07
>0.999
0.34 (0.048–2.363)
HLA-B*51
54 (32%)
42 (14%)
0.000003
0.00008
2.86 (1.406–5.814)
HLA-B*52
5 (3%)
12 (4%)
0.55
>0.999
0.72 (0.139–3.71)
HLA-B*54
2 (1%)
0 (0%)
0.25
>0.999
2.78 (0.022–337.713)
HLA-B*55
2 (1%)
6 (2%)
0.50
>0.999
0.583 (0.048–7.04)
HLA-B*57
2 (1%)
3 (1%)
0.85
>0.999
1.17 (0.072–18.886)
HLA-B*58
2 (1%)
9 (3%)
0.20
>0.999
0.38 (0.034–4.133)
HLA-DRB1*01
8 (5%)
12 (4%)
0.71
>0.999
1.18 (0.339–4.099)
HLA-DRB1*03
12 (7%)
30 (10%)
0.28
>0.999
0.68 (0.261–1.768)
HLA-DRB1*04
9 (5%)
15 (5%)
0.88
>0.999
1.06 (0.333–3.369)
HLA-DRB1*07
7 (4%)
30 (10%)
0.02
0.299
0.387 (0.122–1.21)
HLA-DRB1*08
0 (0%)
3 (1%)
0.99
>0.999
0.58 (0.0001–2918.205)
HLA-DRB1*09
2 (1%)
3 (1%)
0.99
>0.999
1.17 (0.102–13.374)
HLA-DRB1*10
10 (6%)
15 (5%)
0.68
>0.999
1.18 (0.384–3.624)
HLA-DRB1*11
70 (41%)
120 (40%)
0.80
>0.999
1.05 (0.571–1.928)
HLA-DRB1*12
3 (2%)
0 (0%)
0.13
>0.999
5.38 (0.001–27068.86)
HLA-DRB1*13
12 (7%)
30 (10%)
0.28
>0.999
0.68 (0.261–1.768)
HLA-DRB1*14
10 (6%)
21 (7%)
0.63
>0.999
0.83 (0.287–2.4)
HLA-DRB1*15
24 (14%)
9 (3%)
0.000004
0.00006
5.315 (1.806–15.637)
HLA-DRB1*16
3 (2%)
12 (4%)
0.18
>0.999
0.431 (0.075–2.444)
The significant value after Bonferroni correction and OR are shown in bold. aValue of chi-square and Fisher’s exact test without correction. bAdjusted Bonferroni value. ccorrected 95% confidence interval for odds ratio. : number of alleles, NS: not significant, and HD: Hodgkin’s lymphoma.
